These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16478139)

  • 1. NMR distinction of single- and multiple-mode binding of small-molecule protein ligands.
    Reibarkh M; Malia TJ; Wagner G
    J Am Chem Soc; 2006 Feb; 128(7):2160-1. PubMed ID: 16478139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of individual protein-ligand NOEs in the limit of intermediate exchange.
    Reibarkh M; Malia TJ; Hopkins BT; Wagner G
    J Biomol NMR; 2006 Sep; 36(1):1-11. PubMed ID: 16964534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of protein-ligand interactions by NMR.
    Furukawa A; Konuma T; Yanaka S; Sugase K
    Prog Nucl Magn Reson Spectrosc; 2016 Aug; 96():47-57. PubMed ID: 27573180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of protein-ligand interactions by high-resolution solid-state NMR spectroscopy.
    Zech SG; Olejniczak E; Hajduk P; Mack J; McDermott AE
    J Am Chem Soc; 2004 Nov; 126(43):13948-53. PubMed ID: 15506755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule binding sites on proteins established by paramagnetic NMR spectroscopy.
    Guan JY; Keizers PH; Liu WM; Löhr F; Skinner SP; Heeneman EA; Schwalbe H; Ubbink M; Siegal G
    J Am Chem Soc; 2013 Apr; 135(15):5859-68. PubMed ID: 23509882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel approach for characterizing protein ligand complexes: molecular basis for specificity of small-molecule Bcl-2 inhibitors.
    Lugovskoy AA; Degterev AI; Fahmy AF; Zhou P; Gross JD; Yuan J; Wagner G
    J Am Chem Soc; 2002 Feb; 124(7):1234-40. PubMed ID: 11841292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Auto-FACE: an NMR based binding site mapping program for fast chemical exchange protein-ligand systems.
    Krishnamoorthy J; Yu VC; Mok YK
    PLoS One; 2010 Feb; 5(2):e8943. PubMed ID: 20174626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft.
    Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK
    J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy and precision of protein-ligand interaction kinetics determined from chemical shift titrations.
    Markin CJ; Spyracopoulos L
    J Biomol NMR; 2012 Dec; 54(4):355-76. PubMed ID: 23086713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NMR structural investigation of the mitochondrial outer membrane protein VDAC and its interaction with antiapoptotic Bcl-xL.
    Malia TJ; Wagner G
    Biochemistry; 2007 Jan; 46(2):514-25. PubMed ID: 17209561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heat-induced dimerization of BCL-xL through alpha-helix swapping.
    Denisov AY; Sprules T; Fraser J; Kozlov G; Gehring K
    Biochemistry; 2007 Jan; 46(3):734-40. PubMed ID: 17223694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural studies of Bcl-xL/ligand complexes using 19F NMR.
    Yu L; Hajduk PJ; Mack J; Olejniczak ET
    J Biomol NMR; 2006 Apr; 34(4):221-7. PubMed ID: 16645812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of nuclear magnetic resonance in probing ligand-macromolecule interactions.
    Wemmer DE; Williams PG
    Methods Enzymol; 1994; 239():739-67. PubMed ID: 7830603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope mapping and competitive binding of HSA drug site II ligands by NMR diffusion measurements.
    Lucas LH; Price KE; Larive CK
    J Am Chem Soc; 2004 Nov; 126(43):14258-66. PubMed ID: 15506793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Label-free NMR-based dissociation kinetics determination.
    Trigo-Mouriño P; Griesinger C; Lee D
    J Biomol NMR; 2017 Dec; 69(4):229-235. PubMed ID: 29143948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragment-based deconstruction of Bcl-xL inhibitors.
    Barelier S; Pons J; Marcillat O; Lancelin JM; Krimm I
    J Med Chem; 2010 Mar; 53(6):2577-88. PubMed ID: 20192224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.
    Petros AM; Dinges J; Augeri DJ; Baumeister SA; Betebenner DA; Bures MG; Elmore SW; Hajduk PJ; Joseph MK; Landis SK; Nettesheim DG; Rosenberg SH; Shen W; Thomas S; Wang X; Zanze I; Zhang H; Fesik SW
    J Med Chem; 2006 Jan; 49(2):656-63. PubMed ID: 16420051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete relaxation and conformational exchange matrix (CORCEMA) analysis of intermolecular saturation transfer effects in reversibly forming ligand-receptor complexes.
    Jayalakshmi V; Krishna NR
    J Magn Reson; 2002 Mar; 155(1):106-18. PubMed ID: 11945039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unraveling complex small-molecule binding mechanisms by using simple NMR spectroscopy.
    Quinternet M; Starck JP; Delsuc MA; Kieffer B
    Chemistry; 2012 Mar; 18(13):3969-74. PubMed ID: 22336999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.